Protocol for Meningococcal Group B Vaccine (MenB) TRUMENBA® Precautions and Contraindications Screen all patients for precautions and contraindications to immunizations Vaccine Information Statements Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their native language, if one is available and desired; these can be found at . FDA Approved Indications and Usage (See Package Insert, current version dated 1/2015) TRUMENBA is indicated for active immunization to prevent invasive disease caused by serogroup B. Neisseria meningitidis TRUMENBA is approved for use in persons aged 10 through 25 years. ACIP Recommended Use of MenB Vaccines (Note that some of these recommendations differ from the package inserts) High-Risk (See Groups” on page 3) “Eligible TRUMENBA is recommended routinely for use in persons aged 10 through 25 years at increased risk for meningococcal disease attributable to serogroup B. TRUMENBA is recommended routinely for use in persons aged 26 years or older at increased risk for meningococcal disease attributable to serogroup B. Other than High-Risk (See Groups” on page 3) “Eligible TRUMENBA may be administered to adolescents aged 16 through 18 years to provide short-term protection against most strains of serogroup B meningococcal disease. TRUMENBA may be administered to young adults aged 19 through 23 years to provide short-term protection against most strains of serogroup B meningococcal disease. No preference is stated for the use of either of the two currently licensed MenB vaccines,) TRUMENBA (MenB-FHbp) or BEXSERO® (MenB-4C). Because the two MenB vaccines are antigenically different, the same vaccine product must be used for all doses. TRUMENBA is a three-dose series and BEXSERO is a two-dose series.
Protocol for Meningococcal Group B Vaccine (MenB) TRUMENBA® Precautions and Contraindications Screen all patients for precautions and contraindications to immunizations Vaccine Information Statements Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their native language, if one is available and desired; these can be found at . FDA Approved Indications and Usage (See Package Insert, current version dated 1/2015) TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in persons aged 10 through 25 years. ACIP Recommended Use of MenB Vaccines (Note that some of these recommendations differ from the package inserts) High-Risk (See “Eligible Groups” on page 3) TRUMENBA is recommended routinely for use in persons aged 10 through 25 years at increased risk for meningococcal disease attributable to serogroup B. TRUMENBA is recommended routinely for use in persons aged 26 years or older at increased risk for meningococcal disease attributable to serogroup B. Other than High-Risk (See “Eligible Groups” on page 3) TRUMENBA may be administered to adolescents aged 16 through 18 years to provide short-term protection against most strains of serogroup B meningococcal disease. TRUMENBA may be administered to young adults aged 19 through 23 years to provide short-term protection against most strains of serogroup B meningococcal disease. No preference is stated for the use of either of the two currently licensed MenB vaccines,) TRUMENBA (MenB-FHbp) or BEXSERO® (MenB-4C). Because the two MenB vaccines are antigenically different, the same vaccine product must be used for all doses. TRUMENBA is a three-dose series and BEXSERO is a two-dose series.
2016CCSGMenBProtocolTRUMENBAFINAL.docx